2018
Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV?
Rich KM, Bia J, Altice FL, Feinberg J. Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV? Current HIV/AIDS Reports 2018, 15: 266-275. PMID: 29774442, PMCID: PMC6003996, DOI: 10.1007/s11904-018-0396-x.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersCommunity-based harm reduction programsHIV pre-exposure prophylaxisHIV specialty carePre-exposure prophylaxisOpioid treatment programsMultidisciplinary care modelMedication-assisted treatmentBehavioral health servicesPurpose of ReviewToCo-located careHarm reduction programsHarm reduction servicesSpread of HIVTransitional clinicsHCV treatmentHepatitis CPrimary careSpecialty careCare modelPsychiatric careHIVHealth servicesReduction services
2017
Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes
Mazhnaya A, Meteliuk A, Barnard T, Zelenev A, Filippovych S, Altice FL. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. International Journal Of Drug Policy 2017, 47: 187-195. PMID: 28811159, PMCID: PMC5918282, DOI: 10.1016/j.drugpo.2017.07.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCoinfectionFemaleGenotypeHealth ServicesHepacivirusHepatitis CHIV InfectionsHumansInterferon-alphaMalePolyethylene GlycolsProgram DevelopmentProgram EvaluationRecombinant ProteinsRibavirinRisk FactorsSex FactorsSofosbuvirSubstance Abuse, IntravenousSustained Virologic ResponseTreatment OutcomeUkraineYoung AdultConceptsSustained virologic responseHCV treatmentRisk groupsSVR ratesMedical recordsDirect acting antiviral medicationsComparable SVR ratesHCV genotype 3HCV prevalence estimatesHCV treatment servicesActing antiviral (DAA) medicationsCombination of sofosbuvirHigh-risk groupPatient-level outcomesProportion of participantsCommunity-based settingsDAA treatmentVirologic responseAntiviral medicationsHIV characteristicsHCV genotypesIndependent correlatesSVR dataFemale sexGenotype 3
2013
Partner violence and health among HIV-infected jail detainees
Meyer JP, Wickersham JA, Fu JJ, Brown SE, Sullivan TP, Springer SA, Altice FL. Partner violence and health among HIV-infected jail detainees. International Journal Of Prisoner Health 2013, 9: 124-141. PMID: 24376468, PMCID: PMC3873166, DOI: 10.1108/ijph-03-2013-0011.Peer-Reviewed Original ResearchConceptsIntimate partner violenceSubstance use disordersHIV treatment outcomesHealthcare utilizationPartner violenceTreatment outcomesJail detaineesIPV exposureEffects of IPVHIV secondary preventionPost-release interventionsUntreated mental disordersDepth qualitative interviewsLifetime IPV exposureForms of childhoodHigher alcohol use severityCriminal justice populationsAlcohol use severityViolence reductionCJ populationsTime of incarcerationHIV diagnosisSecondary preventionAdulthood abuseQualitative interviewsPatterns of Homelessness and Implications for HIV Health After Release from Jail
Zelenev A, Marcus R, Kopelev A, Cruzado-Quinones J, Spaulding A, Desabrais M, Lincoln T, Altice FL. Patterns of Homelessness and Implications for HIV Health After Release from Jail. AIDS And Behavior 2013, 17: 181-194. PMID: 23657757, PMCID: PMC4625835, DOI: 10.1007/s10461-013-0472-6.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesTreatment outcomesNon-homeless patientsDrug addiction severityUse of alcoholVirological suppressionHIV healthHealth behaviorsJail detaineesMental illnessSubstance abuseAddiction severityMental healthCorrelates of homelessnessIllicit drugsStable housingHousing statusEffects of housingOutcomesHealthDifferent patternsHIVLongitudinal dataPatientsIllness
2012
Correlates of Retention in HIV Care After Release from Jail: Results from a Multi-site Study
Althoff AL, Zelenev A, Meyer JP, Fu J, Brown SE, Vagenas P, Avery AK, Cruzado-Quiñones J, Spaulding AC, Altice FL. Correlates of Retention in HIV Care After Release from Jail: Results from a Multi-site Study. AIDS And Behavior 2012, 17: 156-170. PMID: 23161210, PMCID: PMC3714328, DOI: 10.1007/s10461-012-0372-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase ManagementContinuity of Patient CareFemaleFollow-Up StudiesHealth ServicesHealth Services AccessibilityHIV InfectionsHumansMaleMiddle AgedPatient CompliancePatient DischargePrisonersPrisonsProspective StudiesSecondary PreventionSocial SupportSocial WorkSocioeconomic FactorsYoung AdultConceptsCorrelates of retentionHIV careJail detaineesEffective HIV treatmentCase management servicesReceipt of servicesHIV providersClinic visitsHIV treatmentDischarge planningHeroin useHIV educationMulti-site studyChallenging populationTransportation assistanceCarePost-release periodSustained retentionIncarcerated individualsEmpiric dataCorrelatesReleaseHIVPLWHAProvision of education
2007
Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy
Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. AIDS And Behavior 2007, 12: 284-293. PMID: 18085432, PMCID: PMC2693908, DOI: 10.1007/s10461-007-9336-2.Peer-Reviewed Original ResearchConceptsSelf-administered therapyAntiretroviral therapyDrug usersComposite adherence scorePresence of depressionDrug treatment programsControlled TrialsSix-month periodAdherence scoreOwn medicationsHealth outcomesDAARTMajor causeTherapyAdherenceDiscontinuationHIVSuccessful program designTrialsParticipantsHospitalizationMedicationsLack of willingnessVisits
2006
Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users
Smith-Rohrberg D, Mezger J, Walton M, Bruce RD, Altice FL. Impact of Enhanced Services on Virologic Outcomes in a Directly Administered Antiretroviral Therapy Trial for HIV-Infected Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s48-s53. PMID: 17133204, DOI: 10.1097/01.qai.0000248338.74943.85.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsVirologic outcomesCase management servicesDrug usersVirologic successService utilizationRNA levelsHigher medical service utilizationHIV-1 RNA reductionLog10 HIV-1 RNAAntiretroviral Therapy (SMART) trialImproved virologic outcomesHealth service utilizationHIV-1 RNASelf-administered therapyCopies/mLMedical service utilizationActive drug usersSubstance abuse servicesAntiretroviral therapyHIV outcomesPrimary outcomeProblematic adherenceTherapy trialsDAART